Purpose: Technetium-99m ( 99m Tc) is the radioisotope most widely used in diagnostic nuclear medicine. It is readily available from 99 Mo/ 99m Tc generators as the b À decay product of the 99 Mo (T ½ = 66 h) parent nuclide. This latter is obtained as a fission product in nuclear reactors by neutron-induced reactions on highly enriched uranium. Alternative production routes, such as direct reactions using proton beams on specific target materials [ 100 Mo(p,2n) 96 Tc, and 97m Tc). The aim of this work was to estimate the dose increase (DI) due to the contribution of Tc radioisotopes generated as impurities, after the intravenous injection of four radiopharmaceuticals prepared with cyclotron-produced 99m Tc (CP99m Tc) using 99.05% 100 Mo-enriched metallic targets. Methods: Four 99m Tc radiopharmaceuticals (pertechnetate, sestamibi (MIBI), hexamethylpropyleneamine oxime (HMPAO) and disodium etidronate (HEDP)) were considered in this study. The biokinetic models reported by the International Commission on Radiological Protection (ICRP) for each radiopharmaceutical were used to define the main source organs and to calculate the number of disintegrations per MBq that occurred in each source organ (N source ) for each Tc radioisotope present in the CP99m Tc solution. Then, target organ equivalent doses and effective dose were calculated for each Tc radioisotope with the OLINDA/EXM software versions 1.1 and 2.0, using the calculated N source values and the adult male phantom as program inputs. Total effective dose produced by all Tc isotopes impurities present in the CP99m Tc solution was calculated using the fraction of total activity corresponding to each radioisotope and compared with the effective dose delivered by the generatorproduced 99m Tc. Results: In all cases, the total effective DI of CP99m Tc radiopharmaceuticals calculated with either versions of the OLINDA software was less than 10% from 6 up to 12 h after EOB. Tc are the Tc radioisotopes with the highest concentration in the CP99m Tc solution at EOB. However, their contribution to DI 6 h after EOB is minimal, due to their short half-lives. The radioisotopes with the largest contribution to the effective DI are 96 if administered from 6 to 12 h after the EOB, thus maintaining the effective DI within the 10% limit.
Purpose: Technetium-99m ( 99m Tc) is the radioisotope most widely used in diagnostic nuclear medicine. It is readily available from 99 Mo/ 99m Tc generators as the b À decay product of the 99 Mo (T ½ = 66 h) parent nuclide. This latter is obtained as a fission product in nuclear reactors by neutron-induced reactions on highly enriched uranium. Alternative production routes, such as direct reactions using proton beams on specific target materials [ 100 Mo(p,2n) 99m Tc], have the potential to be both reliable and relatively cost-effective. However, results showed that the 99m Tc extracted from proton-bombarded 100 Mo-enriched targets contains small quantities of several Tc radioisotopes ( 93m Tc, 93 Tc, 94 Tc, 94m Tc, 95 Tc, 95m Tc, 96 Tc, and 97m Tc). The aim of this work was to estimate the dose increase (DI) due to the contribution of Tc radioisotopes generated as impurities, after the intravenous injection of four radiopharmaceuticals prepared with cyclotron-produced 99m Tc (CP99m Tc) using 99.05% 100 Mo-enriched metallic targets. Methods: Four 99m Tc radiopharmaceuticals (pertechnetate, sestamibi (MIBI), hexamethylpropyleneamine oxime (HMPAO) and disodium etidronate (HEDP)) were considered in this study. The biokinetic models reported by the International Commission on Radiological Protection (ICRP) for each radiopharmaceutical were used to define the main source organs and to calculate the number of disintegrations per MBq that occurred in each source organ (N source ) for each Tc radioisotope present in the CP99m Tc solution. Then, target organ equivalent doses and effective dose were calculated for each Tc radioisotope with the OLINDA/EXM software versions 1.1 and 2.0, using the calculated N source values and the adult male phantom as program inputs. Total effective dose produced by all Tc isotopes impurities present in the CP99m Tc solution was calculated using the fraction of total activity corresponding to each radioisotope and compared with the effective dose delivered by the generatorproduced 99m Tc. Results: In all cases, the total effective DI of CP99m Tc radiopharmaceuticals calculated with either versions of the OLINDA software was less than 10% from 6 up to 12 h after EOB.
94m Tc and 93m Tc are the Tc radioisotopes with the highest concentration in the CP99m Tc solution at EOB. However, their contribution to DI 6 h after EOB is minimal, due to their short half-lives. The radioisotopes with the largest contribution to the effective DI are 96 Tc, followed by 95 Tc and 94 Tc. This is due to the types of their emissions and relatively long half-lives, although their concentration in the CP99m Tc solution is five times lower than that of 94m Tc and 93m Tc at the EOB. Conclusions: The increase in the radiation dose caused by other Tc radioisotopes contained in CP99m Tc produced as described here is quite low. Even though the concentrations of the 94 Tc and 95 Tc radioisotopes in the CP99m Tc solution exceed the limits established by the European Pharmacopoeia, CP99m Tc radiopharmaceuticals could be used in routine nuclear medicine diagnostic studies
INTRODUCTION
Technetium-99m ( 99m Tc) is the radioisotope most widely used in diagnostic nuclear medicine. Sodium pertechnetate is used as raw material to prepare more than 20 99m Tc radiopharmaceuticals employed for the detection of diverse physiological and pathological conditions, such as myocardial perfusion, kidney and brain disorders as well as bone metastases. 1 The radioisotope is readily available in hospitals and radiopharmacies from molybdenum-99 (  99 Mo)/   99m Tc generators, as b À decay product of 99 Mo. This is a selected and purified fission product of weapons-grade highly enriched uranium targets. However, the majority of 99 Mo global production derives from less than seven nuclear reactor facilities worldwide, and most of them are close to be permanently shut down at the end of their running periods (more than 50 yrs of operation). Therefore, alternative production routes for both 99 Mo and 99m
Tc are currently being evaluated.
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Among them, the use of cyclotrons to produce either 99 Mo or 99m Tc is one of the most interesting and promising approaches. 5, 6 Experimental studies on 99m Tc production by cyclotrons using the 100 Mo(p,2n) 99m
Tc reaction were initiated within the framework of the "Technetium for hospital/Laboratory of radioisotopes for medicine" (TECHN_OSP/LARAMED) research project, by the Legnaro National Laboratories at the National Institute for Nuclear Physics, Italy (LNL-INFN). 7 Results demonstrated that the direct reaction method is reliable and provides a relatively cost-effective option for the production of 99m Tc. However, gamma-ray spectrometry analyses of the resulting purified  99m Tc solutions demonstrated  the presence of small quantities of several other Tc radioisotopes, such as  93 Tc,   93m   Tc,  94 Tc,  94m Tc,  95 Tc,   95m   Tc,  96 Tc, and   97m Tc. 8 Previous studies reported that the abundance of these contaminant isotopes is basically dependent on different factors, such as the target isotopic composition, proton beam energy, target thickness, irradiation time, and time span from irradiation to injection. 9, 10 Despite the presence of these additional Tc radioisotopes in the solution, all radiopharmaceuticals labeled with cyclotron-produced 99m Tc (CP99m Tc) showed no differences in labeling efficiency, radiochemical purity, and biological behavior when compared to the radiopharmaceuticals labeled with generator-produced 99m Tc (GP99m Tc). 11, 12 Additionally, it was demonstrated that rats scatter-corrected images of myocardial perfusion and bone obtained after injection of radiopharmaceuticals labeled with either CP99m Tc or GP99m Tc were comparable. 11, 13 Selivanova et al. 14 confirmed these results and demonstrated that sodium pertechnetate produced by cyclotron and generator had similar whole body biodistribution in patients.
The main problem with the Tc radioisotopic impurities is that they contribute to the radiation dose to the patient. 9 Thus, the European Pharmacopoeia Commission published a monograph about sodium pertechnetate obtained by proton irradiation of highly enriched molybdenum-100 targets, to set the limits of radioisotopic impurities for the solutions used in clinical diagnosis. 15 The aim of this work was to estimate the increase in the total effective dose due to the contribution of all Tc radioisotopes produced as impurities. Effective dose increase (DI) was calculated for four radiopharmaceuticals prepared with 99m Tc produced by a PETtrace GE cyclotron, evaluating five time points of injection after the end of bombardment (EOB), to identify the time frame when the CP99m Tc radiopharmaceuticals could be used with an acceptable DI.
MATERIALS AND METHODS

Four
99m Tc radiopharmaceuticals were considered for this study, that are most frequently used for clinical diagnosis at the Nuclear Medicine Department of the Veneto Institute of Oncology IOV-IRCCS: sodium pertechnetate, used in clinical diagnosis of thyroid function and morphology; disodium etidronate (HEDP), a phosphonate commonly used for defining bone metastasis in cancer patients; hexamethylpropyleneamine oxime (HMPAO) used as a tracer of brain function; and sestamibi (MIBI) that is widely used in cardiac scans for diagnosis of heart disease. The total effective doses were assessed considering the injection of the four radiopharmaceuticals labeled with either CP99m Tc or GP99m Tc. Cyclotron-produced 99m Tc was obtained by the alternative 100 Mo (p,2n) reaction route using 99.05% 100 Mo-enriched metallic targets (an isotopic composition of which has been considered as a good compromise between the isotope enrichment level and the material cost). 8 Targets were irradiated for 60 min with a 15.7 MeV proton beam using the PETtrace GE medical cyclotron located at St. Orsola-Malpighi Hospital, Nuclear Medicine Department (Bologna, Italy). To determine the relative activities of 99m Tc and the other Tc isotopes, gamma spectrometry measurements were performed after purification of the CP- Tc solution with an automated module based on methyl-ethyl ketone-solvent extraction system. 16 This purification module proved highly efficient, as molybdenum and niobium radioisotope impurities coproduced during the proton irradiation of the 100 Mo-enriched target were below the minimum detectable activity in the extracted and purified CP99m Tc solution. 7, 8, 16 These results were confirmed by Gumiela et al. 17 Table I shows the average relative activity of each Tc radioisotope in the extracted solutions; data were obtained from three experiments and calculated at the EOB. 8 Table II shows the radioisotope impurity limits for human use of sodium pertechnetate, as reported by the European Pharmacopoeia version 9.3, and the fraction of the total activity corresponding to each Tc radioisotope as calculated for the five studied time points after EOB.
2.A. Number of disintegrations in the source organs
The biokinetic models published by the International Commission on Radiological Protection (ICRP) were used to define the source organs for each radiopharmaceutical. Pertechnetate and HEDP biokinetic models were obtained from ICRP publication 53 18 ; HMPAO and MIBI models were obtained from publication 80. 19 The normalized cumulated activities, or number of disintegrations per unit of administered activity in the source regions over time (N source ), were calculated for each radioisotope considering the biological uptake and/or elimination constants reported by the ICRP radiopharmaceutical models.
The number of disintegrations in the bladder (N b ) for each radioisotope was calculated for all four radiopharmaceuticals using the kidney-bladder model presented in ICRP publication 106, 20 according to the following formula:
where fs is the fraction of excreted activity eliminated through the kidneys, ɑ i is the fraction of f s eliminated with the corresponding biological constant k i , k p is the physical decay constant, and t b is the bladder filling and voiding interval (considered a constant of 3.5 h in adults).
Kidney and bladder are the organs that receive the highest dose after injection of phosphonates such as HEDP because phosphonates are mainly eliminated by the kidney. Thus, the number of disintegrations in the kidney (N K ) was calculated using the kidney-bladder model from ICRP 53 according to the following formula, which considers both the kidney uptake and the activity passing through this organ due to excretion:
where f K is the kidney fractional distribution and t K is the mean transit time of phosphonates in the kidney. The other three radiopharmaceuticals are eliminated predominantly by the gastrointestinal (GI) system; therefore, the number of disintegrations that occur in this tract was calculated using the GI model of the OLINDA 1.1 software, 21 which is based on the ICRP 30 GI model. 22 
2.B. Dose calculation
The absorbed dose of each organ was calculated for each Tc radioisotope with the OLINDA 1.1 and OLINDA 2.0 software codes. The OLINDA code version 1.1 uses anthropomorphic phantoms based on the Oak Ridge models; it employs geometrical shapes to define the organs and calculates the effective dose using the tissue weighting factors recommended by ICRP 60. 23 In version 2.0, the geometrical models were replaced by the realistic NURBS-type models, which are based on the recent standardized masses defined by the ICRP in its publication 89 24 ; tissue weighting factors were implemented in accordance with the recommendations of ICRP 103. 25 Both versions of OLINDA software use the RADAR method for internal dose estimation 26 and calculate the equivalent dose in each organ according to the general equation:
where N source is the number of disintegrations occurring in the source organ per unit of activity administered (MBq-h/ MBq), and DF is a dose factor that depends on the radioisotope used, the spatial relationship between the target and the source organs, and their tissue compositions. The dose factor DF is given as:
where m is the mass of the target organ, n i is the number of i-th nuclear transition per nuclear transformation, E i is the mean energy of the i-th nuclear transition, Φ i is the absorbed fraction in the target organ of radiation energy E i emitted from the source organ, w R is the radiation weighting factor assigned to the i-th radiation, and k is a constant whose value depends on the units of the included quantities.
To calculate the equivalent dose delivered to the target organs by the radiopharmaceuticals labeled with each one of the Tc radioisotopes present in the CP99m Tc solution, the calculated number of disintegrations within all source organs for each radioisotope and the adult male phantom were used as program inputs for either versions of OLINDA software. Effective dose (E) per unit of administered activity for each Tc radioisotope was calculated by OLINDA as the tissueweighted sum of the equivalent doses. Total effective dose (E t ) produced by all Tc radioisotopes present in the CP99m Tc solution was calculated for injection at five different times after EOB (6, 8, 10, 12 , and 15 h), using the following equation:
where f i is the fraction of total activity corresponding to each radioisotope i, and E i is the effective dose contribution per unit of activity from each radioisotope i. The values for f i parameters were obtained from the relative activities of Tc isotopes identified in the TECHN_OSP/ LARAMED research project. Finally, the total effective doses calculated at the five time points after EOB were compared with the effective dose delivered by the GP99m Tc radiopharmaceuticals.
RESULTS
The total number of disintegrations in the source organs is directly dependent on the pharmacokinetics of each complex, and the half-life of the radioisotope. Tc are the two radionuclides that produced the highest numbers of disintegrations per unit of administered activity, due to their long half-lives.
It has been demonstrated that the concentration of Tc-MIBI in the source organs can change depending on whether the injection is performed under stress or rest conditions. 27 Thus, the total number of disintegrations in the main source organs after MIBI injection was calculated considering both models. Table IV shows that a higher number of disintegrations can be generally found in the source organs when the test is performed under rest conditions, because the Tc-MIBI concentration in the source organs increases. Muscle and heart are the only organs that present a higher number of disintegrations when injection is carried out under stress conditions.
Radiopharmaceutical effective doses (E) were calculated for each Tc radioisotope and are summarized in Table V . The small differences in the effective dose values obtained with either versions of OLINDA software is attributable to the divergence in the tissue weighting factors and the phantom models used by each version. Table VI shows the total effective dose (mSv/MBq) calculated with both software versions, for the radiopharmaceuticals prepared with pure 99m Tc eluted from a generator (GP99m Tc) and the 99m Tc produced by the cyclotron (CP99m Tc), at different time points after EOB. The increase in effective dose (in percent) caused by the presence of the other Tc radioisotopes is also reported in this table.
In general, the values of effective dose calculated with version 2.0 of OLINDA decreased for Tc-HEDP and Tc-HMPAO, remained the same for Tc-pertechnetate, and increased for Tc-MIBI, as compared to values obtained using version 1.1 (Table VI) . DI after injection of CP99m Tc labeled-radiopharmaceuticals was lower using OLINDA 2.0 except for the case of Tc-HEDP, in which the values remained essentially the same. All radiopharmaceuticals showed the greater DI after 15 h from EOB because the relative concentration of the impurities with longer half-lives increases over time after EOB, as shown in Table II . Figure 1 shows the contribution (in percentage) of each Tc radioisotope to the radiopharmaceutical effective dose at three different time points after EOB (8, 10 , and 12 h), as calculated with both versions of OLINDA. Data for MIBI are reported only for stress condition, because in this case the DI is higher than in rest conditions. 96 Tc is the nuclide with the highest relative activity among the long half-life isotope impurities found. Therefore, it shows the highest contribution to the effective dose, followed by 95 Tc and 94 Tc. The contribution of other Tc radioisotopes is quite low, being at least three orders of magnitude lower than the contribution of 99m Tc.
DISCUSSION
The number of disintegrations in the source organs calculated for each Tc radioisotope after injection of Tc-pertechnetate, Tc-HEDP, and Tc-MIBI is generally in agreement with the data reported by Hou et al. 9 However, some differences were found. Hou et al. did not consider three important source organs (salivary gland, stomach content, and upper large intestine walls) reported in the ICRP biokinetic model to calculate the dose produced by Tc-pertechnetate. They also underestimated the number of disintegrations for the Tc-MIBI model, since liver delayed clearance and gallbladder uptake were not considered for the calculation. The greatest difference was found in the number of disintegrations of Tc-HEDP within the total body. Using the ICRP biokinetic model, our calculated values range between 2 and 9 times higher than values reported by Hou et al.; additionally, they did not clearly stated how the calculations were made. It is not possible to determine whether these differences produced a considerable effect on the calculated total effective dose, by comparison with the results of the present work, because Hou et al. 9 reported the percent of dose difference between cyclotron and reactor-produced Tc, but they did not report the values of total effective dose.
In general, small differences between the total effective doses calculated with either versions of the OLINDA software were expected, since anatomically more accurate phantoms (NURBS) were used in version 2.0. Furthermore, some tissue weighting factor values differ from the version 1.1 (ICRP 60) to version 2.0 (ICRP 103); this results in some tissue equivalent dose increment, as in the case of Tc-MIBI where the rise of the muscle tissue weighting factor from 0.005 to 0.01 produced a higher total effective doses using OLINDA version 2.0 (see Table VI ). However, the DI remained within the 10% limit from 6 to 12 h after EOB for all the CP99m Tc radiopharmaceuticals studied, even when the more accurate version 2.0 of OLINDA was used. 26 Table VI shows that the percent of increase in dose is different for each radiopharmaceutical because the biological uptake and/or clearance rate(s) in each source organ differs among compounds. These results clearly indicate that dose calculation must be performed for each CP99m Tc radiopharmaceutical before its use in a clinical trial, in order to determine the range of time after the EOB when the radiopharmaceuticals can be administered to remain within the 10% limit of DI.
The DI contribution of 94m Tc and 93m
Tc radioisotopes is the most time dependent, since their impact on the dose decreases quickly. Although these Tc radioisotopes are present at the highest concentration in the CP99m Tc solution at the EOB, 6 h later their contribution to the dose is minimal due to their short half-lives (see Table II).  97m Tc,  96 Tc, and   95m Tc radioisotopes have a longer half-life, and tend to increase their dose contribution over time; nonetheless, the Tc-solution (see Fig. 1 ). Table VII compares DI for three Tc radiopharmaceuticals between our experimental results and the theoretical calculations from Hou et al. 9 using OLINDA 1.1 software. They reported a higher dose contribution of Tc-impurities using the same Isoflex Mo target enriched to 99.05%, with a proton beam of 16 MeV but irradiated for 3 h instead of 1 h. Twelve hours after EOB, the increase in effective dose was greater than 10% for Tc-pertechnetate and Tc-MIBI. Tc-HEDP DI remained under 10%, likely as a consequence of the lower number of disintegrations within the total body calculated by the authors. As previously reported by Esposito et al., 6 these results confirm that the dose contribution of Tc-impurities increases with the irradiation time because longer irradiation times are associated not only with a higher production of 99m Tc but also Tc-impurities. Esposito proved that the IP parameter, defined as the ratio of 99m Tc/all Tc isotopes present, is higher at lower irradiation times and reduces when irradiation time increases. Indeed, the IP parameter for a proton beam energy of 15 MeV was about 22% at 1 h, 19.7% at 3 h, and reduced to 16.82% at 6 h. 6 Selivanova et al.
14 reported a 7.58% increase in Tc-pertechnetate effective dose, when assuming an irradiation at 24 MeV for 2 h and an injection time 6 h after EOB; this value is higher than the 5.30% obtained in this work for the same Mo target and injection time. This increment is the consequence of a greater production of 94 Tc, 95 Tc, and 96 Tc radioisotopes at 24 MeV. 96 Technetium was the radioisotope with the highest contribution to the effective dose and is potentially detrimental to the image quality due to its energetic c rays. 8 Thus, the best CP99m Tc production method should generate a minimum amount of 96 Tc. Using a proton beam of 15.7 MeV and an enriched Isoflex Mo target (99.05%), just 0.0267% of the total activity was related to 96 Tc (see Table I ). 8 Selivanova et al. 28 reported a
96
Tc concentration in the Tc-final product of 0.0695%, 0.1478%, and 0.1614% using the same type of Mo target and proton beams of 20, 22, and 24 MeV, respectively. The comparison of these results demonstrates that a low-energy conventional medical cyclotron is preferable, since it produces 99m Tc with less concentration of 96 Tc than medium-energy cyclotrons, as previously reported in the theoretical study by Esposito et al.
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The European Pharmacopoeia limits were set to guarantee that the DI caused by the impurities remains always lower than the 10% limit. However, we believe that these limits apply to large-scale 99m
Tc production after few hours of irradiation and using 20-24 MeV proton beams. Under these conditions, very high-enriched targets (99.815% at least) must be used to maintain the dose under the above-mentioned limit, as demonstrated by Selivanova et al. 28 In this work, 99m
Tc in-house production was achieved using a less expensive 100 Mo metallic target with lower enrichment level (99.05%), shorter irradiation times (1 h), and already available conventional low-energy medical cyclotron (16 MeV) . Under these conditions, the fraction of some Tc-isotope contaminants clearly exceeds the Pharmacopoeia limits. However, the calculated DI contribution by all Tc contaminants present in the 99m Tc-radiopharmaceuticals injected from 6 to 12 h after the EOB still remains within the 10% limit. In addition, the 6-12 h time range after EOB required for using the Tc-solution well matches the time necessary to carry out the separation/purification procedures, terminal sterilization, radiopharmaceutical labeling, and quality control procedure, as described by Martini et al.
7
To calculate the maximum radiation DI after the injection of the CP99m Tc radiopharmaceuticals, the total effective dose values were multiplied by the maximum activity used in clinical practice for each of the radiopharmaceuticals studied. established by the European Pharmacopoeia and based on the Tc impurities obtained in our experimental studies (see Table II ). Clearly, the increment of the dose due to the impurities is minimal. In all cases, the effective dose is lower than the maximum accepted by the World Health Organization for an imaging study (10 mSv) 29 and lower than the effective dose from 370 MBq of 18 FDG (7.03 mSv). 18 
CONCLUSIONS
The percent increase in dose from Tc radioisotope impurities in CP99m Tc is different for each radiopharmaceutical because the biological uptake and/or clearance rate(s) for each source organ differs among compounds. Therefore, a dose assessment study for each radiopharmaceutical, and not just Tc-pertechnetate, is mandatory to determine the time range after EOB that is optimal for the CP99m Tc solution to be used.
A comparative analysis of the data from our target irradiation experiments with those reported by other groups disclosed that the CP99m Tc produced at lower energy (16 MeV) and for shorter irradiation time (60 min) has some advantages. Although the quantity of 99m Tc produced in this way is lower, its radionuclidic purity is higher and the solution can be used for a longer period of time without substantially increasing the absorbed dose.
The radiation absorbed DI due to the contribution of Tc contaminant activity present in the CP99m Tc produced by the beam irradiation conditions reported in this work is relatively low. However, its impact should not be underestimated. Overall, the concentrations of the two 94 Tc and 95 Tc radioisotopes in the CP- Tc exceed the limits established by the European Pharmacopoeia for all the time points studied; nonetheless, radiopharmaceuticals labeled with this CP99m Tc solution could be used in routine nuclear medicine diagnostic studies if administered from 6 to 12 h after the EOB because the dose increment remains within the 10% limit. 
